Agrinnovate India
Series A in 2015
Agrinnovate India Ltd., established in 2011 under the Companies Act, is a for-profit entity owned by the Department of Agricultural Research & Education (DARE), Ministry of Agriculture, Government of India. The company serves as a bridge between the Indian Council of Agricultural Research (ICAR) and various stakeholders in the agricultural sector, including farmers, public and private firms, research organizations, and educational institutions both nationally and internationally. Its primary goal is to secure, sustain, and promote global agricultural development through intellectual property rights protection and fostering innovation in agricultural research and development.
Avraham Pharmaceuticals
Venture Round in 2014
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Private Equity Round in 2013
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Venture Round in 2011
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Series A in 2010
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.